New drug combo aims to tame stubborn high blood pressure
NCT ID NCT07030101
First seen Jun 25, 2026 · Last updated Jul 10, 2026 · Updated 2 times
Summary
This Phase 3 trial tests a new drug called TCA108 for adults with uncontrolled hypertension (high blood pressure). About 400 participants who are already on two blood pressure medications will receive either TCA108 or other standard treatments for 10 weeks. The main goal is to see if TCA108 lowers systolic blood pressure more than existing options.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TCA108 (a new combination drug for blood pressure)
- What this could lead to
- If successful, this could provide a new treatment option for people whose high blood pressure is not controlled by current medications.
- What could go wrong
- This is an early Phase 3 trial, so results are not yet known. The new drug may not be more effective than existing treatments, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we stop early artery aging in kids with kidney disease?
- Can a few short nights of sleep tip the scales toward high blood pressure?
- Chatbot could put blood pressure control in Patients' hands
- Can a 5-Step chat help tame high blood pressure?
- Can artery scans reveal hidden damage from high blood pressure?
- CRISPR injection could rewrite the future of blood pressure control